- Home
- PHAR vs WDI Comparison
PHAR vs WDI Comparison
Compare PHAR & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- WDI
- Stock Information
- Founded
- PHAR 1988
- WDI 2021
- Country
- PHAR Netherlands
- WDI United States
- Employees
- PHAR N/A
- WDI N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- WDI Trusts Except Educational Religious and Charitable
- Sector
- PHAR Health Care
- WDI Finance
- Exchange
- PHAR Nasdaq
- WDI Nasdaq
- Market Cap
- PHAR 951.7M
- WDI 788.9M
- IPO Year
- PHAR N/A
- WDI N/A
- Fundamental
- Price
- PHAR $13.18
- WDI $14.36
- Analyst Decision
- PHAR Strong Buy
- WDI
- Analyst Count
- PHAR 3
- WDI 0
- Target Price
- PHAR $30.00
- WDI N/A
- AVG Volume (30 Days)
- PHAR 9.7K
- WDI 192.6K
- Earning Date
- PHAR 11-06-2025
- WDI 01-01-0001
- Dividend Yield
- PHAR N/A
- WDI 11.80%
- EPS Growth
- PHAR N/A
- WDI N/A
- EPS
- PHAR N/A
- WDI 1.12
- Revenue
- PHAR $339,836,000.00
- WDI N/A
- Revenue This Year
- PHAR $17.70
- WDI N/A
- Revenue Next Year
- PHAR $12.25
- WDI N/A
- P/E Ratio
- PHAR N/A
- WDI $12.82
- Revenue Growth
- PHAR 22.44
- WDI N/A
- 52 Week Low
- PHAR $7.31
- WDI $12.16
- 52 Week High
- PHAR $17.08
- WDI $14.69
- Technical
- Relative Strength Index (RSI)
- PHAR 43.85
- WDI 32.55
- Support Level
- PHAR $13.03
- WDI $14.26
- Resistance Level
- PHAR $13.43
- WDI $14.50
- Average True Range (ATR)
- PHAR 0.49
- WDI 0.18
- MACD
- PHAR -0.10
- WDI -0.01
- Stochastic Oscillator
- PHAR 23.47
- WDI 29.71
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.